Tawanda Gumbo

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi request reprint Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Curr Opin Drug Discov Devel 11:32-42. 2008
  2. doi request reprint Therapy duration and long-term outcomes in extra-pulmonary tuberculosis
    Tobias Pusch
    Department of Medicine, University of Texas Southwestern Medical Center, Dallas, USA
    BMC Infect Dis 14:115. 2014
  3. pmc Quantification of echodensities in tuberculous pericardial effusion using fractal geometry: a proof of concept study
    Mpiko Ntsekhe
    Department of Medicine, The Cardiac Clinic, Groote Schuur Hospital and University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
    Cardiovasc Ultrasound 10:30. 2012
  4. pmc Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 50:3695-700. 2006
  5. pmc Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs
    Tawanda Gumbo
    Division of Infectious Diseases, Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 53:3197-204. 2009
  6. ncbi request reprint Population pharmacokinetics of micafungin in adult patients
    Tawanda Gumbo
    Ordway Research Institute, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 60:329-31. 2008
  7. ncbi request reprint Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, Dallas, Texas 75390 9113, USA
    Curr Opin Infect Dis 20:587-91. 2007
  8. pmc Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
    Tawanda Gumbo
    Division of Infectious Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:3781-8. 2007
  9. pmc Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:2329-36. 2007
  10. pmc Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia
    Tawanda Gumbo
    Division of Infectious Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:968-74. 2007

Collaborators

Detail Information

Publications41

  1. ncbi request reprint Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Curr Opin Drug Discov Devel 11:32-42. 2008
    ..The result is a rational starting point in drug regimen design. Such regimens can then be compared with standard therapies in randomized clinical trials...
  2. doi request reprint Therapy duration and long-term outcomes in extra-pulmonary tuberculosis
    Tobias Pusch
    Department of Medicine, University of Texas Southwestern Medical Center, Dallas, USA
    BMC Infect Dis 14:115. 2014
    ..While much focus has been paid to pulmonary tuberculosis, EPTB has received scant attention. Moreover, EPTB is viewed as one wastebasket diagnosis, as "the other" which is not pulmonary...
  3. pmc Quantification of echodensities in tuberculous pericardial effusion using fractal geometry: a proof of concept study
    Mpiko Ntsekhe
    Department of Medicine, The Cardiac Clinic, Groote Schuur Hospital and University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
    Cardiovasc Ultrasound 10:30. 2012
    ....
  4. pmc Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 50:3695-700. 2006
    ..This pharmacokinetic-pharmacodynamic picture of anidulafungin persistence in tissues and the resultant persistent fungal decline should be exploited to improve the efficacy of anidulafungin therapy for candidemia...
  5. pmc Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs
    Tawanda Gumbo
    Division of Infectious Diseases, Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 53:3197-204. 2009
    ....
  6. ncbi request reprint Population pharmacokinetics of micafungin in adult patients
    Tawanda Gumbo
    Ordway Research Institute, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 60:329-31. 2008
    ..3 kg above which serum clearance increased by approximately 50%. Patients with weight >66.3 kg may need larger doses to achieve similar exposures to those <66.3 kg. However, the clinical implications are still unknown...
  7. ncbi request reprint Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, Dallas, Texas 75390 9113, USA
    Curr Opin Infect Dis 20:587-91. 2007
    ..This review examines recent advances in echinocandin pharmacokinetics and pharmacodynamics, and discusses how these studies could lead to newer dosing strategies for the treatment of invasive candidiasis...
  8. pmc Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
    Tawanda Gumbo
    Division of Infectious Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:3781-8. 2007
    ..tuberculosis, (ii) the achievement of a free C(max)/MIC of >175 that can be tolerated by patients, and (iii) a long postantibiotic effect duration...
  9. pmc Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:2329-36. 2007
    ....
  10. pmc Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia
    Tawanda Gumbo
    Division of Infectious Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:968-74. 2007
    ..Once-weekly micafungin therapy is as efficacious as daily therapy in a murine model of disseminated candidiasis...
  11. ncbi request reprint Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth
    Tawanda Gumbo
    Emerging Infections and Host Defenses Section, Ordway Research Institute, Albany, NY, USA
    J Infect Dis 195:194-201. 2007
    ..We examined the veracity of this cornerstone belief...
  12. ncbi request reprint In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens
    Shashikant Srivastava
    Department of Internal Medicine, UT Southwestern Medical Center at Dallas, Texas 75390, USA
    Curr Pharm Des 17:2881-8. 2011
    ..In addition, PK/PD driven doses have been proposed for new anti-tuberculosis agents such as moxifloxacin and PA-824...
  13. pmc New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 54:1484-91. 2010
    ..With the proposed breakpoints, the rates of multidrug-resistant tuberculosis could become 4-fold higher than currently assumed...
  14. ncbi request reprint Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
    Tawanda Gumbo
    Emerging Infections and Host Defense Section, Ordway Research Institute, Albany, New York 12208, USA
    J Infect Dis 190:1642-51. 2004
    ..To optimize moxifloxacin dose and dose regimen, pharmacodynamic antibiotic-exposure targets associated with maximal microbial kill and complete suppression of drug resistance in M. tuberculosis must be identified...
  15. pmc Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability
    Shashikant Srivastava
    Department of Medicine, University of Texas Southwestern Medical Center at Dallas, TX, USA
    J Infect Dis 204:1951-9. 2011
    ..Performance of a randomized controlled trial in which some patients are randomized to nonadherence would be unethical; therefore, other study designs should be utilized...
  16. pmc Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Antimicrob Agents Chemother 56:1502-7. 2012
    ..On the other hand, such reduced AUCs could lead to therapy failure. Thus, new and individualized ethambutol dosing regimens need to be designed for obese and extremely obese patients...
  17. pmc Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection
    Devyani Deshpande
    Division of Infectious Diseases, Department of Medicine, UT Southwestern Medical Center, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 54:2534-9. 2010
    ..For patients infected with susceptible isolates, however, 800 mg a day should be examined for safety and efficacy for disseminated M. avium disease...
  18. pmc Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling
    Shashikant Srivastava
    Department of Medicine, UT Southwestern Medical Center at Dallas, Texas 75390 8507, USA
    Antimicrob Agents Chemother 55:5085-9. 2011
    ..tuberculosis killing. We conclude that current efforts aimed at better pharmacokinetic matching to decrease M. tuberculosis resistance emergence are likely futile and counterproductive...
  19. pmc The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance
    Aurelia M Schmalstieg
    Department of Medicine, University of Texas Southwestern Medical Center, School of Pharmacy, Dallas, Texas, USA
    Antimicrob Agents Chemother 56:4806-15. 2012
    ....
  20. pmc Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium
    Devyani Deshpande
    Division of Infectious Diseases, UT Southwestern Medical Center, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 54:1728-33. 2010
    ..avium in Middlebrook broth. Given that the modal MIC of clinical isolates is around 2 mg/liter, most isolates should be considered ethambutol resistant...
  21. pmc Serum drug concentrations predictive of pulmonary tuberculosis outcomes
    Jotam G Pasipanodya
    Office of Global Health, University of Texas Southwestern Medical Center, Dallas, Texas
    J Infect Dis 208:1464-73. 2013
    ..Based on a hollow-fiber system model of tuberculosis, we hypothesize that microbiologic failure and acquired drug resistance are primarily driven by low drug concentrations that result from pharmacokinetic variability...
  22. pmc Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Antimicrob Agents Chemother 57:2259-64. 2013
    ..This study protocol was registered at www.clinicaltrials.gov under registration number NCT01062165.)...
  23. pmc Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity
    Arnold Louie
    Emerging Infections and Pharmacodynamics Laboratory, Ordway Research Institute, 150 New Scotland Avenue, Albany, New York 12208, USA
    Antimicrob Agents Chemother 49:5058-68. 2005
    ....
  24. ncbi request reprint Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Clin Infect Dis 44:79-86. 2007
    ..Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models...
  25. pmc Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance
    Tawanda Gumbo
    Emerging Infections and Host Defense Theme, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208, USA
    Antimicrob Agents Chemother 49:3178-81. 2005
    ..One of the explanations for why early bactericidal activity fails to predict sterilization may be the emergence of a resistant subpopulation, which only becomes >/=1% at the end of the early bactericidal activity studies...
  26. ncbi request reprint The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations
    G L Drusano
    Ordway Research Institute, Albany, NY 12208, USA
    Clin Infect Dis 42:525-32. 2006
    ..In each instance, quinolone antimicrobials were examined. More investigations with other pathogens and drug classes are required...
  27. pmc Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol
    Shashikant Srivastava
    Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9113, USA
    J Infect Dis 201:1225-31. 2010
    ..Ethambutol is used for the treatment of tuberculosis in cases where there is isoniazid resistance. We examined the emergence of drug resistance to ethambutol monotherapy in pharmacokinetic-pharmacodynamic studies of a hollow-fiber system...
  28. doi request reprint Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium
    Devyani Deshpande
    Division of Infectious Diseases, UT Southwestern Medical Center, Dallas, TX 75390 9113, USA
    Future Microbiol 6:433-9. 2011
    ..Use of pharmacodynamic/pharmacokinetic models has resulted in design of new doses and dosing schedules for disseminated MAC, as well as new susceptibility breakpoints for ethambutol and moxifloxacin...
  29. pmc A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients
    Jotam G Pasipanodya
    Office of Global Health and Department of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390 8507, USA
    Clin Infect Dis 57:21-31. 2013
    ..We evaluated the superiority of directly observed therapy (DOT) for tuberculosis patients vs self-administered therapy (SAT) in decreasing ADR, microbiologic failure, and relapse in meta-analyses...
  30. pmc Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners
    Sandirai Musuka
    Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Antimicrob Agents Chemother 57:5870-7. 2013
    ..Therefore, the way forward for phenothiazine monotherapy that also reduces therapy duration is via synthesis of less toxic congeners. ..
  31. pmc In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis
    Prakash M Jeena
    Department of Paediatrics and Child Health, University of KwaZulu Natal, Durban, South Africa
    Antimicrob Agents Chemother 55:539-45. 2011
    ..We conclude that current recommended doses for children are likely suboptimal and that isoniazid doses in children are best individualized based on disease process, age, and acetylation status...
  32. pmc Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, Texas 75235, USA
    Pharmacotherapy 29:1468-81. 2009
    ..These patient factors, the covariates for pharmacokinetic variability, and PK-PD factors suggest the need to individualize therapy for patients with tuberculosis in order to optimize outcomes and reduce the duration of therapy...
  33. pmc Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection
    Mamta K Jain
    UT Southwestern Medical Center, Department of Internal Medicine, Dallas, TX, USA
    Antimicrob Agents Chemother 57:1115-20. 2013
    ..Optimizing dose to patient weight and PEGIFN AUC in the first week offers a solution to improve SVR and to potentially shorten duration of therapy...
  34. pmc Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophages
    Jennifer L Eitson
    The Department of Immunology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Appl Environ Microbiol 78:6829-37. 2012
    ..In summary, a pSUM-protein expression vector and a mammalian IL-6 reporter cell line provide new tools for understanding the pathogenic mechanisms deployed by various mycobacterial species...
  35. pmc Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used
    Jotam G Pasipanodya
    UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 54:2847-54. 2010
    ..098 (CI, 0.047 to 0.193) at 60 mg/kg of pyrazinamide. Thus, high-dose pyrazinamide did not significantly increase hepatotoxicity. This suggests that a considerable portion of hepatotoxicity rates may be idiosyncratic...
  36. pmc An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future
    Jotam Pasipanodya
    Division of Infectious Diseases, UT Southwestern Medical Center at Dallas, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 55:24-34. 2011
    ..These steps outline a more rational approach than that of current methods for designing regimens and predicting outcome so that both new and older antituberculosis agents can shorten therapy duration...
  37. pmc Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people
    Ronald G Hall
    Texas Tech University Health Sciences Center and UT Southwestern Medical Center, 2 Dallas, Texas 75390 9113, USA
    Antimicrob Agents Chemother 55:5107-12. 2011
    ..Furthermore, micafungin SCL continues to increase as weight increases, with no obvious plateau. This leads to a requirement for strategies to determine individualized dosing levels for obese and extremely obese patients...
  38. pmc A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs
    Jotam G Pasipanodya
    Department of Medicine, UT Southwestern Medical Center, Dallas, TX 75390 9113, USA
    Curr Opin Pharmacol 11:457-63. 2011
    ....
  39. doi request reprint Meningeal tuberculosis: high long-term mortality despite standard therapy
    Joanna E T Shaw
    University of Texas Southwestern Medical Center, Dallas, Texas 75390 9113, USA
    Medicine (Baltimore) 89:189-95. 2010
    ..07% of controls. The long-term outlook in patients with proven tuberculous meningitis adequately treated with current standard tuberculous therapy is bleak. A re-examination of treatment strategies is urgently needed...
  40. pmc Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing
    William W Hope
    Pediatric Oncology Branch, NCI NIH, CRC Room 1 5750, Bethesda, MD 20892 1100, USA
    Antimicrob Agents Chemother 51:3714-9. 2007
    ....
  41. ncbi request reprint Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenon
    Tawanda Gumbo
    Department of Infectious Diseases, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Scand J Infect Dis 34:817-8. 2002
    ..2-130] and chronic renal failure (OR 14.7; 95% CI 1.2-184). These data suggest that careful long-term follow-up of patients with C. glabrata fungemia is important and present an opportunity to explore secondary prophylaxis...

Research Grants3

  1. PK-PD of combination antituberculosis therapy for suppression of drug-resistance
    Tawanda Gumbo; Fiscal Year: 2010
    ..A particularly big problem is the emergence of multidrug resistant tuberculosis. The current application will apply pharmacokinetic-pharmacodynamic solutions to this public health problem. ..